# Phase 1 pancreatic cancer trials recruiting: 97 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 97 trials in phase 1 for pancreatic cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 1 pancreatic cancer trials: 97 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 3 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-1/pancreatic-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 97
- Recruiting or not yet: 97
- Read on: November 19, 2026

## Trials

The 25 newest of 97, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 10, 2026 | NCT07929961 | Study of MC001 in Patients With Advanced Solid Tumours | National University Hospital, Singapore | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Nasopharyngeal Carcinoma, Advanced Solid Tumours | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07929961) |
| November 2, 2026 | NCT07909356 | A Study of MC001 in Patients With Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) and Other Folate Receptor Alpha... | Medicovestor, Inc | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma (PDAC), Advanced Solid Tumor Cancer, Metastatic Pancreatic Cancer, Metastatic Solid... | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07909356) |
| October 30, 2026 | NCT07906691 | A Study to Assess the Effect of Itraconazole on the Pharmacokinetics of HRS-4642 Following Intravenous Infusion in Healthy Participants | Shanghai Hengrui Pharmaceutical Co., Ltd. | Phase 1 | Not yet recruiting | Pancreatic Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07906691) |
| October 29, 2026 | NCT07903415 | A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors. | Pfizer | Phase 1 | Recruiting | Pancreatic Ductal Adenocarcinoma, Esophageal Cancer, Carcinoma, Non-Small-Cell Lung (NSCLC), Gastric Carcinoma... | 280 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07903415) |
| October 27, 2026 | NCT07898813 | Daraxonrasib in Resectable PDAC | Dana-Farber Cancer Institute | Phase 1 | Not yet recruiting | Pancreatic Ductal Adenocarcinoma, Pancreatic Cancer, Resectable Pancreatic Ductal Adenocarcinoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07898813) |
| October 15, 2026 | NCT07875920 | Phase 1 Study of NW-301V TCR-T Cells in Advanced Solid Tumors With KRAS G12V Mutation | Neowise Biotechnology | Phase 1 | Not yet recruiting | Advanced Solid Cancer, Pancreatic Ductal Adenocarcinoma (PDAC), Colorectal Adenocarcinoma, Lung Adenocarcinoma, KRAS... | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07875920) |
| September 18, 2026 | NCT07828236 | Lm-LLO-TT and Gemcitabine in Unresectable Pancreatic Ductal Adenocarcinoma | Loki Therapeutics, Inc. | Phase 1 | Recruiting | Pancreas Cancer, Duct Cell Adenocarcinoma, Pancreatic Cancer, Advanced Pancreatic Adenocarcinoma | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07828236) |
| September 16, 2026 | NCT07822399 | A Study of MGC030 in Participants With Advanced Solid Tumors | MacroGenics | Phase 1 | Recruiting | Urothelial Cancer, GastroEsophageal Cancer, Colorectal Cancer, Esophageal Cancer, Gastric Cancer (GC), Pancreatic Cancer | 314 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07822399) |
| September 1, 2026 | NCT07796997 | GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy | University of Illinois Chicago | Phase 1 | Not yet recruiting | Pancreatic Cancer, Pancreatic Adenocarcinoma, Duodenal Cancer, Distal Cholangiocarcinoma | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07796997) |
| August 13, 2026 | NCT07763301 | YMN-136 Vaccine for Patients With Advanced Hepatobiliary and Pancreatic Malignancies | West China Hospital | Phase 1 | Recruiting | Liver Cancer, Pancreatic Cancer, Biliary Tract Cancer (BTC) | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763301) |
| August 10, 2026 | NCT07756281 | First in Human Study of SNV1521 With a RAS Inhibitor for People With Advanced Pancreatic Cancer | ParVation Therapeutics, Inc. | Phase 1 | Recruiting | Pancreatic Cancer, Pancreatic Acinar Carcinoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07756281) |
| July 29, 2026 | NCT07733674 | Study of 203Pb-RMX-VH-PIB Dosimetry and Biodistribution in Patients With Glioblastoma Multiform (GBM) and Pancreatic Ductal Adenocarcinoma... | Radiomedix, Inc. | Phase 1 | Recruiting | Glioblastoma Multiforme (GBM), Pancreatic Ductal Adenocarcinoma (PDAC) | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07733674) |
| July 16, 2026 | NCT07707674 | Phase I Open-Label Randomized Multicenter Study of XNW28012 Monotherapy in Metastatic Pancreatic Cancer | Evopoint Biosciences Inc. | Phase 1 | Not yet recruiting | Metastatic Pancreatic Cancer | 24 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07707674) |
| June 26, 2026 | NCT07671339 | A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer | Memorial Sloan Kettering Cancer Center | Phase 1 | Recruiting | Pancreatic Cancer | 20 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07671339) |
| June 16, 2026 | NCT07650357 | A Study of CLSP 5282 in HLA-A\*03:01 Positive Adult Patients With Solid Tumors (SENTINEL-101) | Clasp Therapeutics, Inc. | Phase 1 | Not yet recruiting | Advanced Solid Tumor, Non Small Cell Lung Cancer, Pancreatic Carcinoma, Colorectal Cancer | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07650357) |
| June 2, 2026 | NCT07619313 | AB801 in Combination With Chemotherapy and Immunotherapy for the Treatment of Patients With Borderline Resectable, Locally Advanced or... | Jonsson Comprehensive Cancer Center | Phase 1 | Recruiting | Borderline Resectable Pancreatic Ductal Adenocarcinoma, Locally Advanced Cholangiocarcinoma, Locally Advanced... | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07619313) |
| May 27, 2026 | NCT07608627 | 64Cu-DOTA A2 scFv-Fc2 DM With Positron Emission Tomography for the Imaging of Patients With Locally Advanced or Metastatic PSCA-Expressing... | City of Hope Medical Center | Phase 1 | Not yet recruiting | Locally Advanced Pancreatic Adenocarcinoma, Metastatic Pancreatic Adenocarcinoma, Stage III Pancreatic Cancer AJCC v8... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07608627) |
| May 14, 2026 | NCT07587827 | Study Evaluating the Safety Feasibility and Efficacy of ODI-2001 Vaccine, a Personnalized Immunotherapy in Patients With Metastatic or... | Centre Georges Francois Leclerc | Phase 1 | Not yet recruiting | Metastatic Colorectal Cancer (CRC), Locally Advanced Colorectal Cancer, Metastatic Pancreatic Cancer, Locally Advanced... | 77 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07587827) |
| April 28, 2026 | NCT07553793 | Chimeric Antigen Receptor Macrophages Targeting c-MET for Advanced Stage of Pancreatic Cancer Patients | Peking Union Medical College Hospital | Phase 1 | Not yet recruiting | Pancreatic Cancer, Advanced Stage Cancer | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07553793) |
| April 24, 2026 | NCT07549958 | PhIbRandomGemcitabine(G)w/or w/Out Pitavastatin(P)MainTx UnresecPancreaticAdenocarcinoma(uPDAC) | University of California, Irvine | Phase 1 | Recruiting | Pancreatic Cancer, Pancreatic Cancer Metastatic | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07549958) |
| March 18, 2026 | NCT07481383 | A First-in-Human Study to Evaluate Implantable Iontophoresis Chemotherapy Delivery Device With Gemcitabine Once Weekly or Twice Weekly in... | Continuity Biosciences, LLC | Phase 1 | Recruiting | Pancreatic Adenocarcinoma Non-resectable | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07481383) |
| March 9, 2026 | NCT07458347 | A Phase 1 Dose Escalation and Dose Expansion Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral... | Kestrel Therapeutics, Inc. | Phase 1 | Recruiting | KRAS-mutant Non-small Cell Lung Cancer (NSCLC), KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC), KRAS-mutant... | 545 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07458347) |
| February 23, 2026 | NCT07425483 | CAR-NK Cells (CL-NK-003) in Pancreatic Cancer | Changhai Hospital | Phase 1 | Recruiting | Pancreatic Cancer | 9 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07425483) |
| January 16, 2026 | NCT07349537 | Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors | Revolution Medicines, Inc. | Phase 1 | Recruiting | Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal... | 574 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349537) |
| December 23, 2025 | NCT07300150 | A Study of PT0511 in Participants With KRAS Mutated or Amplified Advanced Solid Tumors | PAQ Therapeutics, Inc. | Phase 1 | Recruiting | Colorectal Cancer, Pancreatic Cancer, Non-Small Cell Lung Cancer, Solid Tumor | 210 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07300150) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| National Cancer Institute (NCI) | 4 |
| [Chongqing Precision Biotech Co., Ltd](https://specstream.ai/data/clinical-trials/company/chongqing-precision-biotech-co-ltd) | 3 |
| [MacroGenics](https://specstream.ai/data/clinical-trials/company/macrogenics) | 3 |
| City of Hope Medical Center | 2 |
| Washington University School of Medicine | 2 |
| UNC Lineberger Comprehensive Cancer Center | 2 |
| [Pfizer](https://specstream.ai/data/clinical-trials/company/pfizer) | 2 |
| University of California, San Diego | 2 |
| [Revolution Medicines, Inc.](https://specstream.ai/data/clinical-trials/company/revolution-medicines-inc) | 2 |
| Second Affiliated Hospital of Guangzhou Medical University | 2 |
| Changhai Hospital | 2 |
| [Sichuan Baili Pharmaceutical Co., Ltd.](https://specstream.ai/data/clinical-trials/company/sichuan-baili-pharmaceutical-co-ltd) | 2 |
| [Eli Lilly and Company](https://specstream.ai/data/clinical-trials/company/eli-lilly-and-company) | 2 |
| Sichuan University | 2 |
| MOMA Therapeutics | 1 |
| Peking Union Medical College Hospital | 1 |
| Degron Therapeutics Co. | 1 |
| Abramson Cancer Center at Penn Medicine | 1 |
| University of California, Irvine | 1 |
| Kestrel Therapeutics, Inc. | 1 |
| RasCal Therapeutics, Inc. | 1 |
| IDEAYA Biosciences | 1 |
| Peking University | 1 |
| PanTher Therapeutics | 1 |
| Continuity Biosciences, LLC | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 63 |
| China | 29 |
| Australia | 8 |
| South Korea | 6 |
| Spain | 5 |
| United Kingdom | 4 |
| Canada | 4 |
| France | 3 |
| Japan | 3 |
| Taiwan | 2 |
| Puerto Rico | 1 |
| Egypt | 1 |
| Singapore | 1 |
| Italy | 1 |
| Poland | 1 |
| Sweden | 1 |
| Israel | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Public utilities in the United States](https://specstream.ai/data/businesses/public-utilities/united-states)
- [3D printing companies in the United States](https://specstream.ai/data/businesses/3d-printing-companies/united-states)
- [Computer hardware companies in the United States](https://specstream.ai/data/businesses/computer-hardware-companies/united-states)
- [Hong Kong style cafes in the United States](https://specstream.ai/data/businesses/hong-kong-style-cafes/united-states)
- [Pediatric surgery practices in the United States](https://specstream.ai/data/businesses/pediatric-surgery-practices/united-states)
- [TV service providers in the United States](https://specstream.ai/data/businesses/tv-service-providers/united-states)
